Although early clinical trials have been positive, peptide vaccine mechanism of action (how tolerance is induced) is unknown. The primary objective of these studies is to identify changes in gene expression and cytokine expression that are correlated with vaccine treatment. These changes could provide insight to mechanisms of action and may reveal potential genetic biomarkers […]

The Cat-SPIRE vaccine reduces symptoms in those who suffer from cat allergy. Two interns will work on complementary projects that will evaluate blood and nasal biomarkers of Cat-SPIRE efficacy. One trainee will examine changes to the DNA in special immune cells called dendritic cells, isolated from blood. The other trainee will examine markers of inflammation […]

Adiga Life Sciences Inc. developed a novel immunotherapeutic platform in which small components (peptides) of allergen proteins are identified and administered in a regimen that causes immune cells to become non-responsive towards the allergens. In a phase II clinical trial, the cat allergy treatment developed by Adiga using this platform reduced allergic symptoms in allergic […]

Allergic rhinitis is an inflammatory condition of the nasal passages induced after allergen exposure in sensitized individuals. Approximately 20-25% of Canadians suffer from allergic rhinitis, with cat allergy affecting up to 15% of people with allergic rhinitis and/or asthma. Although existing immunotherapies have some effectiveness, these have safety problems and require long-term treatment. A novel […]

Adiga Life Sciences Inc. developed a novel immunotherapeutic platform in which small components (peptides) of allergen proteins are identified and administered in a regimen that causes immune cells to become non-responsive towards the allergens. In a phase II clinical trial, the cat allergy treatment developed by Adiga using this platform reduced allergic symptoms in allergic […]